IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myeloma
New findings reveal that combining daratumumab with lenalidomide significantly enhances MRD negativity and progression-free survival in multiple myeloma maintenance therapy.
